IRCCS, Policlinico San Donato, San Donato Milanese, Milan, Italy.
IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
J Arthroplasty. 2014 Aug;29(8):1516-20. doi: 10.1016/j.arth.2014.02.024. Epub 2014 Feb 26.
An RCT was conducted to ascertain whether, compared to control management, topical application of a novel fibrin sealant (Evicel, J&J) in patients undergoing primary TKA reduces peri-operative blood loss. Sixty-two patients were randomized to receive topical application of Evicel (N = 31) or not (N = 31). The mean total blood loss was 1.9L(± 0.7) in the control group and 1.8L(± 0.5) in the treatment group (P = 0.4). The transfusion rate was 32.3% in the control group and 25.8% in the treatment group (P = 0.5). The transfusion rate decreased linearly with increasing preoperative Hb levels in the treatment group (P = 0.005). The results of this study suggest that topical application of this novel fibrin sealant doesn't reduce perioperative blood loss and the need for allogeneic blood transfusion.
一项 RCT 旨在确定与对照管理相比,在接受初次 TKA 的患者中局部应用新型纤维蛋白密封剂(Evicel,J&J)是否可减少围手术期失血。将 62 名患者随机分为接受 Evicel 局部应用组(N = 31)或不接受组(N = 31)。对照组的平均总失血量为 1.9L(±0.7),治疗组为 1.8L(±0.5)(P = 0.4)。对照组的输血率为 32.3%,治疗组为 25.8%(P = 0.5)。治疗组的输血率随术前 Hb 水平的增加呈线性下降(P = 0.005)。本研究结果表明,局部应用这种新型纤维蛋白密封剂不能减少围手术期失血和异体输血的需求。